P/B
1,8
Adagene
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
$161.1M
Market Cap • 10/15/2026
2011
(15 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
China
Country
Valuation
P/S
17,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,3
EPS
—
Market Cap
Market Cap
161,1M
EV
55,9M
EV/Revenue
6
EV/EBITDA
-2,5
EV/EBIT
-2,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-42,5%
Total Yield
-42,5%
Payout
0%
Retained Earnings
-345,2M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
258,1%
Capex/Revenue
1,8%
Capex/D&A
44,4%
Capex/OCF
-0,9%
SBC/OCF
—
% PPE
0,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
39,6%
CAGR Op. Income 5Y
-18,3%
CAGR Net Income 5Y
-19,7%
CAGR EPS 5Y
-33,7%
Leverage
N.D./EBITDA
5,5
Debt/Equity
0%
Current Ratio
5
Quick Ratio
4,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!